Docking-based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models.

G protein-coupled receptors (GPCRs) regulate a wide range of physiological functions and hold great pharmaceutical interest. Using the β(2)-adrenergic receptor as a case study, this article explores the applicability of docking-based virtual screening to the discovery of GPCR ligands and defines methods intended to improve the screening performance. Our controlled computational experiments were performed on a compound dataset containing known agonists and blockers of the receptor as well as a large number of decoys. The screening based on the structure of the receptor crystallized in complex with its inverse agonist carazolol yielded excellent results, with a clearly delineated prioritization of ligands over decoys. Blockers generally were preferred over agonists; however, agonists were also well distinguished from decoys. A method was devised to increase the screening yields by generating an ensemble of alternative conformations of the receptor that accounts for its flexibility. Moreover, a method was devised to improve the retrieval of agonists, based on the optimization of the receptor around a known agonist. Finally, the applicability of docking-based virtual screening also to homology models endowed with different levels of accuracy was proved. This last point is of uttermost importance, since crystal structures are available only for a limited number of GPCRs, and extends our conclusions to the entire superfamily. The outcome of this analysis definitely supports the application of computer-aided techniques to the discovery of novel GPCR ligands, especially in light of the fact that, in the near future, experimental structures are expected to be solved and become available for an ever increasing number of GPCRs.

[1]  Stefano Costanzi,et al.  A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. , 2008, Journal of the American Chemical Society.

[2]  Nagarajan Vaidehi,et al.  Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation. , 2008, Biophysical journal.

[3]  Claudio N. Cavasotto and Narender Singh Docking and High Throughput Docking: Successes and the Challenge of Protein Flexibility , 2008 .

[4]  Michel Bouvier,et al.  Insights into signaling from the beta2-adrenergic receptor structure. , 2008, Nature chemical biology.

[5]  Gerhard Hummer,et al.  Atomistic insights into rhodopsin activation from a dynamic model. , 2008, Journal of the American Chemical Society.

[6]  Peter L. Freddolino,et al.  Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Holger Gohlke,et al.  Target flexibility: an emerging consideration in drug discovery and design. , 2008, Journal of medicinal chemistry.

[8]  Marta Filizola,et al.  Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[10]  Peter Kolb,et al.  Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.

[11]  M. Gershengorn,et al.  Seven Transmembrane-spanning Receptors for Free Fatty Acids as Therapeutic Targets for Diabetes Mellitus: Pharmacological, Phylogenetic, and Drug Discovery Aspects* , 2008, Journal of Biological Chemistry.

[12]  Claudio N. Cavasotto,et al.  Conformational Sampling of Protein Flexibility in Generalized Coordinates: Application to Ligand Docking , 2005 .

[13]  Stefano Costanzi,et al.  Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. , 2008, Journal of medicinal chemistry.

[14]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[15]  Ruben Abagyan,et al.  Identifying conformational changes of the β2 adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators , 2009, J. Comput. Aided Mol. Des..

[16]  Stefano Costanzi,et al.  On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. , 2008, Journal of medicinal chemistry.

[17]  G. Müller Towards 3D structures of G protein-coupled receptors: a multidisciplinary approach. , 2000, Current medicinal chemistry.

[18]  M. Gershengorn,et al.  Two Arginine-Glutamate Ionic Locks Near the Extracellular Surface of FFAR1 Gate Receptor Activation* , 2009, Journal of Biological Chemistry.

[19]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[20]  Stefano Costanzi,et al.  Identification of Residues Important for Agonist Recognition and Activation in GPR40* , 2007, Journal of Biological Chemistry.

[21]  B. Shoichet,et al.  Soft docking and multiple receptor conformations in virtual screening. , 2004, Journal of medicinal chemistry.

[22]  Somesh D. Sharma,et al.  Managing protein flexibility in docking and its applications. , 2009, Drug discovery today.

[23]  Santiago Vilar,et al.  Ligand and structure‐based models for the prediction of ligand‐receptor affinities and virtual screenings: Development and application to the β2‐adrenergic receptor , 2009, J. Comput. Chem..

[24]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[25]  J. Ballesteros,et al.  The Forgotten Serine , 2000, The Journal of Biological Chemistry.

[26]  Claudio N. Cavasotto,et al.  2,3‐Dihydro‐1‐Benzofuran Derivatives as a Series of Potent Selective Cannabinoid Receptor 2 Agonists: Design, Synthesis, and Binding Mode Prediction through Ligand‐Steered Modeling , 2009, ChemMedChem.

[27]  Claudio N. Cavasotto,et al.  Ligand-Steered Modeling and Docking: A Benchmarking Study in Class A G-Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..

[28]  Claudio N. Cavasotto,et al.  Representing receptor flexibility in ligand docking through relevant normal modes. , 2005, Journal of the American Chemical Society.

[29]  Claudio N. Cavasotto,et al.  Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.

[30]  K. Jacobson,et al.  Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. , 2005, Journal of medicinal chemistry.

[31]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[32]  B. Raaka,et al.  Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. , 2007, Journal of medicinal chemistry.

[33]  D. Rognan,et al.  Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.

[34]  Dov Barak,et al.  Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.

[35]  Claudio N. Cavasotto,et al.  Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. , 2008, Journal of medicinal chemistry.

[36]  Sharangdhar S. Phatak,et al.  6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction. , 2009, Journal of medicinal chemistry.

[37]  Raymond C Stevens,et al.  Discovery of new GPCR biology: one receptor structure at a time. , 2009, Structure.

[38]  Olivier Sperandio,et al.  How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis , 2010, European Biophysics Journal.

[39]  C. Strader,et al.  Structure and function of G protein-coupled receptors. , 1994, Annual review of biochemistry.

[40]  I. Tikhonova,et al.  Unraveling the structure and function of G protein-coupled receptors through NMR spectroscopy. , 2009, Current pharmaceutical design.

[41]  Nagarajan Vaidehi,et al.  Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor. , 2010, Journal of the American Chemical Society.

[42]  Stefano Costanzi,et al.  Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. , 2009, Current pharmaceutical design.

[43]  B. Raaka,et al.  Understanding the structural and functional differences between mouse thyrotropin‐releasing hormone receptors 1 and 2 , 2008, Proteins.

[44]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..